25 XP   0   0   10

Entrada Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Entrada Therapeutics Inc together

PenkeI guess you are interested in Entrada Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Entrada Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Entrada Therapeutics Inc

I send you an email if I find something interesting about Entrada Therapeutics Inc.

Quick analysis of Entrada Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Entrada Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.21
Expected worth in 1 year
$8.10
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$0.89
Return On Investment
7.2%

For what price can you sell your share?

Current Price per Share
$12.36
Expected price per share
$10.75 - $16.50
How sure are you?
50%

1. Valuation of Entrada Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$12.36

Intrinsic Value Per Share

$3.00 - $3.69

Total Value Per Share

$10.22 - $10.91

2. Growth of Entrada Therapeutics Inc (5 min.)




Is Entrada Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$242.3m$244.8m-$13.4m-5.8%

How much money is Entrada Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.6m-$22.2m$20.5m1,228.8%
Net Profit Margin-27.7%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Entrada Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#215 / 1010

Most Revenue
#188 / 1010

Most Profit
#279 / 1010

Most Efficient
#503 / 1010

What can you expect buying and holding a share of Entrada Therapeutics Inc? (5 min.)

Welcome investor! Entrada Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Entrada Therapeutics Inc.

What can you expect buying and holding a share of Entrada Therapeutics Inc?

First you should know what it really means to hold a share of Entrada Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Entrada Therapeutics Inc is $12.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Entrada Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Entrada Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.21. Based on the TTM, the Book Value Change Per Share is $0.22 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.64 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Entrada Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-2.3%-0.20-1.6%-0.70-5.7%-0.41-3.3%-0.41-3.3%
Usd Book Value Change Per Share0.121.0%0.221.8%-0.64-5.2%0.554.5%0.554.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.121.0%0.221.8%-0.64-5.2%0.554.5%0.554.5%
Usd Price Per Share15.09-15.13-12.71-9.88-9.88-
Price to Earnings Ratio-13.28--4.75--4.48--3.44--3.44-
Price-to-Total Gains Ratio125.92-37.24--19.79-7.93-7.93-
Price to Book Ratio2.09-2.23-1.79-1.38-1.38-
Price-to-Total Gains Ratio125.92-37.24--19.79-7.93-7.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.36
Number of shares80
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.220.55
Usd Total Gains Per Share0.220.55
Gains per Quarter (80 shares)17.7444.39
Gains per Year (80 shares)70.96177.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1071610178168
201421320355346
302132030533524
402842740710702
503553450888880
60426416010651058
70497487012431236
80568558014201414
90639629015981592
100710700017751770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.012.00.07.7%1.012.00.07.7%1.012.00.07.7%
Book Value Change Per Share3.01.00.075.0%4.07.01.033.3%4.08.01.030.8%4.08.01.030.8%4.08.01.030.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share3.01.00.075.0%4.07.01.033.3%4.08.01.030.8%4.08.01.030.8%4.08.01.030.8%

Fundamentals of Entrada Therapeutics Inc

About Entrada Therapeutics Inc

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-22 02:04:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Entrada Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Entrada Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -22.8% means that $-0.23 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Entrada Therapeutics Inc:

  • The MRQ is -22.8%. The company is making a huge loss. -2
  • The TTM is -27.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-22.8%TTM-27.7%+4.9%
TTM-27.7%YOY--27.7%
TTM-27.7%5Y-8.5%-19.2%
5Y-8.5%10Y-8.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.8%-207.2%+184.4%
TTM-27.7%-216.8%+189.1%
YOY--282.3%+282.3%
5Y-8.5%-436.8%+428.3%
10Y-8.5%-597.3%+588.8%
1.1.2. Return on Assets

Shows how efficient Entrada Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • -2.0% Return on Assets means that Entrada Therapeutics Inc generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Entrada Therapeutics Inc:

  • The MRQ is -2.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.0%TTM-0.3%-1.7%
TTM-0.3%YOY-7.9%+7.5%
TTM-0.3%5Y-7.4%+7.0%
5Y-7.4%10Y-7.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.0%-13.3%+11.3%
TTM-0.3%-12.8%+12.5%
YOY-7.9%-11.6%+3.7%
5Y-7.4%-13.8%+6.4%
10Y-7.4%-15.6%+8.2%
1.1.3. Return on Equity

Shows how efficient Entrada Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • -3.9% Return on Equity means Entrada Therapeutics Inc generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Entrada Therapeutics Inc:

  • The MRQ is -3.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.9%TTM-1.2%-2.7%
TTM-1.2%YOY-9.2%+7.9%
TTM-1.2%5Y-3.7%+2.4%
5Y-3.7%10Y-3.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.9%-16.9%+13.0%
TTM-1.2%-16.1%+14.9%
YOY-9.2%-14.9%+5.7%
5Y-3.7%-19.3%+15.6%
10Y-3.7%-20.1%+16.4%

1.2. Operating Efficiency of Entrada Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Entrada Therapeutics Inc is operating .

  • Measures how much profit Entrada Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 11.7% means the company generated $0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Entrada Therapeutics Inc:

  • The MRQ is 11.7%. The company is operating less efficient.
  • The TTM is -11.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ11.7%TTM-11.7%+23.4%
TTM-11.7%YOY--11.7%
TTM-11.7%5Y-3.6%-8.1%
5Y-3.6%10Y-3.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7%-298.0%+309.7%
TTM-11.7%-238.5%+226.8%
YOY--288.4%+288.4%
5Y-3.6%-486.2%+482.6%
10Y-3.6%-628.4%+624.8%
1.2.2. Operating Ratio

Measures how efficient Entrada Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.88 means that the operating costs are $0.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Entrada Therapeutics Inc:

  • The MRQ is 0.883. The company is less efficient in keeping operating costs low.
  • The TTM is 1.192. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.883TTM1.192-0.309
TTM1.192YOY-+1.192
TTM1.1925Y0.367+0.825
5Y0.36710Y0.3670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8833.235-2.352
TTM1.1923.310-2.118
YOY-3.838-3.838
5Y0.3675.679-5.312
10Y0.3677.823-7.456

1.3. Liquidity of Entrada Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Entrada Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.33 means the company has $2.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Entrada Therapeutics Inc:

  • The MRQ is 2.329. The company is able to pay all its short-term debts. +1
  • The TTM is 2.671. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.329TTM2.671-0.342
TTM2.671YOY13.042-10.371
TTM2.6715Y15.165-12.494
5Y15.16510Y15.1650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3293.863-1.534
TTM2.6714.169-1.498
YOY13.0425.337+7.705
5Y15.1656.122+9.043
10Y15.1656.434+8.731
1.3.2. Quick Ratio

Measures if Entrada Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.05 means the company can pay off $4.05 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Entrada Therapeutics Inc:

  • The MRQ is 4.055. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.065. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.055TTM4.065-0.010
TTM4.065YOY19.212-15.147
TTM4.0655Y15.065-11.001
5Y15.06510Y15.0650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0553.504+0.551
TTM4.0653.991+0.074
YOY19.2125.371+13.841
5Y15.0656.088+8.977
10Y15.0656.395+8.670

1.4. Solvency of Entrada Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Entrada Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Entrada Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.48 means that Entrada Therapeutics Inc assets are financed with 48.3% credit (debt) and the remaining percentage (100% - 48.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Entrada Therapeutics Inc:

  • The MRQ is 0.483. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.518. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.483TTM0.518-0.035
TTM0.518YOY0.141+0.377
TTM0.5185Y0.733-0.215
5Y0.73310Y0.7330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4830.339+0.144
TTM0.5180.337+0.181
YOY0.1410.271-0.130
5Y0.7330.368+0.365
10Y0.7330.388+0.345
1.4.2. Debt to Equity Ratio

Measures if Entrada Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 93.6% means that company has $0.94 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Entrada Therapeutics Inc:

  • The MRQ is 0.936. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.090. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.936TTM1.090-0.154
TTM1.090YOY0.165+0.925
TTM1.0905Y0.388+0.702
5Y0.38810Y0.3880.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9360.392+0.544
TTM1.0900.403+0.687
YOY0.1650.335-0.170
5Y0.3880.427-0.039
10Y0.3880.461-0.073

2. Market Valuation of Entrada Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Entrada Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Entrada Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -13.28 means the investor is paying $-13.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Entrada Therapeutics Inc:

  • The EOD is -10.879. Based on the earnings, the company is expensive. -2
  • The MRQ is -13.282. Based on the earnings, the company is expensive. -2
  • The TTM is -4.753. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.879MRQ-13.282+2.403
MRQ-13.282TTM-4.753-8.529
TTM-4.753YOY-4.483-0.270
TTM-4.7535Y-3.441-1.311
5Y-3.44110Y-3.4410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.879-2.300-8.579
MRQ-13.282-2.656-10.626
TTM-4.753-2.718-2.035
YOY-4.483-4.145-0.338
5Y-3.441-6.258+2.817
10Y-3.441-6.315+2.874
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Entrada Therapeutics Inc:

  • The EOD is -20.811. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -25.408. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.393. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.811MRQ-25.408+4.597
MRQ-25.408TTM-8.393-17.015
TTM-8.393YOY-4.459-3.935
TTM-8.3935Y-4.460-3.933
5Y-4.46010Y-4.4600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.811-2.974-17.837
MRQ-25.408-3.306-22.102
TTM-8.393-3.508-4.885
YOY-4.459-5.613+1.154
5Y-4.460-8.378+3.918
10Y-4.460-8.873+4.413
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Entrada Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.09 means the investor is paying $2.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Entrada Therapeutics Inc:

  • The EOD is 1.714. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.092. Based on the equity, the company is underpriced. +1
  • The TTM is 2.225. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.714MRQ2.092-0.378
MRQ2.092TTM2.225-0.133
TTM2.225YOY1.786+0.439
TTM2.2255Y1.382+0.843
5Y1.38210Y1.3820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7141.914-0.200
MRQ2.0922.116-0.024
TTM2.2252.097+0.128
YOY1.7862.881-1.095
5Y1.3823.550-2.168
10Y1.3823.936-2.554
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Entrada Therapeutics Inc.

3.1. Institutions holding Entrada Therapeutics Inc

Institutions are holding 78.739% of the shares of Entrada Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP14.48110.8355486581900
2023-12-31Mpm Asset Management, LLC13.171532.8181442578400
2023-12-315AM Venture Management, LLC13.119717.6461440837900
2023-12-31T. Rowe Price Associates, Inc.8.95710.0061300967396360.3212
2023-12-31BlackRock Inc4.47170.00061502537981346.9876
2023-09-30Redmile Group, LLC3.82130.96531284000-27572-2.1022
2023-12-31Vanguard Group Inc3.170.00041065166448494.3956
2023-12-31Wellington Management Company LLP3.11830.003104778021280.2035
2023-12-31StepStone Group LLC2.26562.067676127700
2023-12-31TCG Crossover Management, LLC1.74090.978958495500
2023-12-31FMR Inc1.59380.0006535523-46593-8.0041
2023-12-31Geode Capital Management, LLC1.36720.0007459381208004.7426
2023-12-31State Street Corporation1.27330.0003427832245796.0952
2023-12-31American Century Companies Inc0.71020.00252386459984771.9369
2023-12-31Northern Trust Corp0.59730.0006200688-4373-2.1325
2023-12-3172 Investment Holdings, LLC0.513711.5652172600-336423-66.0919
2023-12-31Charles Schwab Investment Management Inc0.45050.0006151358-3866-2.4906
2023-12-31TD Asset Management Inc0.35490.001811925400
2023-12-31Bank of New York Mellon Corp0.34240.00041150604810771.8519
2023-12-31Advantage Alpha Capital Partners, LP0.31290.30031051371051370
Total 75.833467.194625480848+34390+0.1%

3.2. Funds holding Entrada Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31US Small-Cap Growth II Equity Comp5.28750.1081776650-5680-0.3187
2023-12-31T. Rowe Price New Horizons5.28750.10841776650-5680-0.3187
2024-02-29Vanguard Total Stock Mkt Idx Inv1.79180.000560207200
2023-12-31T. Rowe Price Health Sciences1.62530.056546106-11353-2.0366
2024-03-28iShares Russell 2000 ETF1.52550.01115126002460.048
2023-12-31T. Rowe Price New Horizons Tr-Z0.94980.111331912756801.8121
2024-03-29Avantis US Small Cap Value ETF0.93020.040831256800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.8540.0037286951-408-0.142
2024-02-29Fidelity Select Biotechnology0.68950.0623231671-75834-24.6611
2024-01-31Fidelity Small Cap Index0.64590.012821702333021.545
2024-03-28iShares Russell 2000 Value ETF0.60280.0229202555-128-0.0632
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.40470.004513597900
2024-02-29Fidelity Extended Market Index0.32110.0037107883-523-0.4824
2024-03-29Schwab US Small-Cap ETF™0.27250.00769157600
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.2390.01178030000
2024-02-29Vanguard Russell 2000 ETF0.2310.01087762660528.4556
2023-12-31TD Health Sciences - I0.17750.07195962700
2023-12-31NT R2000 Value Index Fund - NL0.1760.023659135-3642-5.8015
2023-12-31NT R2000 Index Fund - NL0.17470.012258716-3534-5.6771
2024-02-29Schwab Small Cap Index0.15030.01135051700
Total 22.33660.69517505332-91502-1.2%

3.3. Insider Transactions

Insiders are holding 15.461% of the shares of Entrada Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08Peter S KimBUY260013.57
2024-03-28Peter S KimBUY151213.75
2024-03-25Peter S KimBUY318013.36
2024-03-21Peter S KimBUY70413.24
2024-03-19Peter S KimBUY90012.66
2024-02-15Dipal DoshiSELL100015
2024-01-16Dipal DoshiSELL100015.99
2023-12-26Kory James WentworthSELL9416.67
2023-12-22Kory James WentworthSELL1020615.69
2023-12-20Dipal DoshiSELL100015
2023-11-13Dipal DoshiSELL100016.23
2023-10-17Dipal DoshiSELL100015
2023-09-13Dipal DoshiSELL100015
2023-09-06Kory James WentworthSELL95013.48
2023-09-06Nerissa KreherSELL89213.48
2023-09-06Nathan J DowdenSELL97213.47
2023-08-14Dipal DoshiSELL100015.67
2023-08-04Nerissa KreherSELL689814.14
2023-08-02Nerissa KreherSELL1034815.19
2023-07-11Kory James WentworthSELL388418

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Entrada Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1200.222-46%-0.641+635%0.555-78%0.555-78%
Book Value Per Share--7.2136.824+6%7.286-1%4.534+59%4.534+59%
Current Ratio--2.3292.671-13%13.042-82%15.165-85%15.165-85%
Debt To Asset Ratio--0.4830.518-7%0.141+242%0.733-34%0.733-34%
Debt To Equity Ratio--0.9361.090-14%0.165+467%0.388+141%0.388+141%
Dividend Per Share----0%-0%-0%-0%
Eps---0.284-0.202-29%-0.704+148%-0.414+46%-0.414+46%
Free Cash Flow Per Share---0.1481.005-115%-0.719+384%-0.058-61%-0.058-61%
Free Cash Flow To Equity Per Share---0.1281.161-111%-0.716+459%0.696-118%0.696-118%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.695--------
Intrinsic Value_10Y_min--3.005--------
Intrinsic Value_1Y_max---0.091--------
Intrinsic Value_1Y_min---0.090--------
Intrinsic Value_3Y_max--0.078--------
Intrinsic Value_3Y_min--0.067--------
Intrinsic Value_5Y_max--0.670--------
Intrinsic Value_5Y_min--0.592--------
Market Cap415309596.000-22%507040599.000513107332.200-1%427153983.750+19%333561238.138+52%333561238.138+52%
Net Profit Margin---0.228-0.277+22%--100%-0.085-63%-0.085-63%
Operating Margin--0.117-0.117+199%-+100%-0.036+131%-0.036+131%
Operating Ratio--0.8831.192-26%-+100%0.367+141%0.367+141%
Pb Ratio1.714-22%2.0922.225-6%1.786+17%1.382+51%1.382+51%
Pe Ratio-10.879+18%-13.282-4.753-64%-4.483-66%-3.441-74%-3.441-74%
Price Per Share12.360-22%15.09015.1330%12.713+19%9.885+53%9.885+53%
Price To Free Cash Flow Ratio-20.811+18%-25.408-8.393-67%-4.459-82%-4.460-82%-4.460-82%
Price To Total Gains Ratio103.139-22%125.92037.242+238%-19.788+116%7.930+1488%7.930+1488%
Quick Ratio--4.0554.0650%19.212-79%15.065-73%15.065-73%
Return On Assets---0.020-0.003-83%-0.079+287%-0.074+263%-0.074+263%
Return On Equity---0.039-0.012-68%-0.092+133%-0.037-6%-0.037-6%
Total Gains Per Share--0.1200.222-46%-0.641+635%0.555-78%0.555-78%
Usd Book Value--242360000.000231385750.000+5%244801000.000-1%152990769.231+58%152990769.231+58%
Usd Book Value Change Per Share--0.1200.222-46%-0.641+635%0.555-78%0.555-78%
Usd Book Value Per Share--7.2136.824+6%7.286-1%4.534+59%4.534+59%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.284-0.202-29%-0.704+148%-0.414+46%-0.414+46%
Usd Free Cash Flow---4989000.00033547250.000-115%-24168250.000+384%-2000076.923-60%-2000076.923-60%
Usd Free Cash Flow Per Share---0.1481.005-115%-0.719+384%-0.058-61%-0.058-61%
Usd Free Cash Flow To Equity Per Share---0.1281.161-111%-0.716+459%0.696-118%0.696-118%
Usd Market Cap415309596.000-22%507040599.000513107332.200-1%427153983.750+19%333561238.138+52%333561238.138+52%
Usd Price Per Share12.360-22%15.09015.1330%12.713+19%9.885+53%9.885+53%
Usd Profit---9544000.000-1671250.000-82%-22206750.000+133%-11948461.538+25%-11948461.538+25%
Usd Revenue--41848000.00032253250.000+30%-+100%9924076.923+322%9924076.923+322%
Usd Total Gains Per Share--0.1200.222-46%-0.641+635%0.555-78%0.555-78%
 EOD+2 -6MRQTTM+14 -19YOY+22 -115Y+16 -1710Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Entrada Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.879
Price to Book Ratio (EOD)Between0-11.714
Net Profit Margin (MRQ)Greater than0-0.228
Operating Margin (MRQ)Greater than00.117
Quick Ratio (MRQ)Greater than14.055
Current Ratio (MRQ)Greater than12.329
Debt to Asset Ratio (MRQ)Less than10.483
Debt to Equity Ratio (MRQ)Less than10.936
Return on Equity (MRQ)Greater than0.15-0.039
Return on Assets (MRQ)Greater than0.05-0.020
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Entrada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.463
Ma 20Greater thanMa 5013.070
Ma 50Greater thanMa 10013.140
Ma 100Greater thanMa 20014.002
OpenGreater thanClose12.230
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -2,0571,415-642-363-1,005509-496691195



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets469,192
Total Liabilities226,832
Total Stockholder Equity242,360
 As reported
Total Liabilities 226,832
Total Stockholder Equity+ 242,360
Total Assets = 469,192

Assets

Total Assets469,192
Total Current Assets369,771
Long-term Assets99,421
Total Current Assets
Cash And Cash Equivalents 67,602
Short-term Investments 284,367
Net Receivables 7,578
Other Current Assets 10,224
Total Current Assets  (as reported)369,771
Total Current Assets  (calculated)369,771
+/-0
Long-term Assets
Property Plant Equipment 92,681
Long-term Assets Other 2,790
Long-term Assets  (as reported)99,421
Long-term Assets  (calculated)95,471
+/- 3,950

Liabilities & Shareholders' Equity

Total Current Liabilities158,796
Long-term Liabilities68,036
Total Stockholder Equity242,360
Total Current Liabilities
Short-term Debt 7,909
Accounts payable 3,277
Other Current Liabilities 15,349
Total Current Liabilities  (as reported)158,796
Total Current Liabilities  (calculated)26,535
+/- 132,261
Long-term Liabilities
Capital Lease Obligations 68,230
Long-term Liabilities  (as reported)68,036
Long-term Liabilities  (calculated)68,230
+/- 194
Total Stockholder Equity
Common Stock3
Retained Earnings -194,970
Accumulated Other Comprehensive Income 195
Other Stockholders Equity 437,132
Total Stockholder Equity (as reported)242,360
Total Stockholder Equity (calculated)242,360
+/-0
Other
Capital Stock3
Cash and Short Term Investments 351,969
Common Stock Shares Outstanding 33,369
Current Deferred Revenue132,261
Liabilities and Stockholders Equity 469,192
Net Debt 628
Net Invested Capital 242,360
Net Working Capital 210,975
Property Plant and Equipment Gross 98,604
Short Long Term Debt Total 68,230



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-03-31
> Total Assets 
0
0
43,527
0
143,514
132,395
305,833
316,702
295,917
274,463
252,056
475,569
493,983
485,033
469,192
469,192485,033493,983475,569252,056274,463295,917316,702305,833132,395143,514043,52700
   > Total Current Assets 
0
0
39,949
137,636
137,636
123,525
298,700
272,712
253,903
234,733
209,875
434,135
390,195
383,043
369,771
369,771383,043390,195434,135209,875234,733253,903272,712298,700123,525137,636137,63639,94900
       Cash And Cash Equivalents 
0
0
39,045
0
136,947
122,172
291,064
84,640
90,867
53,311
45,157
227,648
376,789
51,882
67,602
67,60251,882376,789227,64845,15753,31190,86784,640291,064122,172136,947039,04500
       Short-term Investments 
0
0
0
0
0
0
0
179,262
153,387
162,261
143,555
183,983
297,046
301,696
284,367
284,367301,696297,046183,983143,555162,261153,387179,2620000000
       Net Receivables 
0
0
0
0
0
2,969
872
0
0
0
0
6,297
3,744
5,025
7,578
7,5785,0253,7446,29700008722,96900000
       Other Current Assets 
0
0
904
0
689
1,353
7,636
8,810
9,649
19,161
21,163
16,207
9,662
29,465
10,224
10,22429,4659,66216,20721,16319,1619,6498,8107,6361,353689090400
   > Long-term Assets 
0
0
3,578
0
5,878
8,870
7,133
43,990
42,014
39,730
42,181
41,434
103,788
101,990
99,421
99,421101,990103,78841,43442,18139,73042,01443,9907,1338,8705,87803,57800
       Property Plant Equipment 
0
0
3,037
5,087
5,087
5,901
6,261
38,606
37,189
34,826
33,021
23,641
99,300
95,059
92,681
92,68195,05999,30023,64133,02134,82637,18938,6066,2615,9015,0875,0873,03700
       Other Assets 
0
0
0
791
791
2,969
305,833
5,384
4,825
4,904
9,160
0
4,488
0
0
004,48809,1604,9044,8255,384305,8332,969791791000
> Total Liabilities 
0
0
85,017
0
202,528
204,986
7,115
39,311
39,878
41,243
39,502
245,957
287,075
238,370
226,832
226,832238,370287,075245,95739,50241,24339,87839,3117,115204,986202,528085,01700
   > Total Current Liabilities 
0
0
3,359
4,536
4,536
7,158
6,719
15,426
18,077
21,551
21,972
147,594
125,940
165,433
158,796
158,796165,433125,940147,59421,97221,55118,07715,4266,7197,1584,5364,5363,35900
       Short-term Debt 
0
0
0
0
0
0
0
7,971
8,114
8,259
8,406
7,103
7,409
6,642
7,909
7,9096,6427,4097,1038,4068,2598,1147,9710000000
       Accounts payable 
0
0
1,602
1,881
1,881
2,278
706
2,931
4,622
1,341
5,990
6,474
2,422
752
3,277
3,2777522,4226,4745,9901,3414,6222,9317062,2781,8811,8811,60200
       Other Current Liabilities 
0
0
1,757
413
2,655
4,880
6,013
4,524
5,341
11,951
7,576
11,676
14,464
9,599
15,349
15,3499,59914,46411,6767,57611,9515,3414,5246,0134,8802,6554131,75700
   > Long-term Liabilities 
0
0
81,658
0
197,992
197,828
396
23,885
21,801
19,692
17,530
98,363
161,135
72,937
68,036
68,03672,937161,13598,36317,53019,69221,80123,885396197,828197,992081,65800
       Warrants
0
0
0
0
0
197,489
0
0
0
0
0
0
0
0
0
000000000197,48900000
       Other Liabilities 
0
0
0
503
503
339
396
0
0
0
0
0
95,511
0
0
0095,51100000396339503503000
       Deferred Long Term Liability 
0
0
0
0
0
2,200
0
0
0
0
0
0
0
0
0
0000000002,20000000
> Total Stockholder Equity
0
0
-41,490
0
-59,014
-72,591
298,718
277,391
256,039
233,220
212,554
229,612
206,908
246,663
242,360
242,360246,663206,908229,612212,554233,220256,039277,391298,718-72,591-59,0140-41,49000
   Common Stock
0
0
0
1
1
0
3
3
3
3
3
3
3
3
3
333333333011000
   Retained Earnings Total Equity00000000-93,669-75,22200000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-1,535
-2,265
-2,747
-2,057
-642
-1,005
-496
195
195-496-1,005-642-2,057-2,747-2,265-1,5350000000
   Capital Surplus 
0
0
0
0
0
2,631
392,384
0
0
0
0
0
0
0
0
00000000392,3842,63100000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
1,021
0
1,778
-194,858
392,384
394,263
396,820
399,620
402,893
425,210
428,797
432,582
437,132
437,132432,582428,797425,210402,893399,620396,820394,263392,384-194,8581,77801,02100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue129,013
Cost of Revenue-2,841
Gross Profit126,172126,172
 
Operating Income (+$)
Gross Profit126,172
Operating Expense-129,334
Operating Income-3,162-3,162
 
Operating Expense (+$)
Research Development97,043
Selling General Administrative32,291
Selling And Marketing Expenses0
Operating Expense129,334129,334
 
Net Interest Income (+$)
Interest Income15,218
Interest Expense-0
Other Finance Cost-3,342
Net Interest Income11,876
 
Pretax Income (+$)
Operating Income-3,162
Net Interest Income11,876
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,056-18,380
EBIT - interestExpense = -3,162
12,056
-6,685
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-3,16212,056
Earnings Before Interest and Taxes (EBITDA)-321
 
After tax Income (+$)
Income Before Tax12,056
Tax Provision-18,741
Net Income From Continuing Ops-21,770-6,685
Net Income-6,685
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses132,175
Total Other Income/Expenses Net15,218-11,876
 

Technical Analysis of Entrada Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Entrada Therapeutics Inc. The general trend of Entrada Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Entrada Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Entrada Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.51 < 15.57 < 16.50.

The bearish price targets are: 11.35 > 11.24 > 10.75.

Tweet this
Entrada Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Entrada Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Entrada Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Entrada Therapeutics Inc. The current macd is -0.2531668.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Entrada Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Entrada Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Entrada Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Entrada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEntrada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Entrada Therapeutics Inc. The current adx is 16.72.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Entrada Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Entrada Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Entrada Therapeutics Inc. The current sar is 14.03.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Entrada Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Entrada Therapeutics Inc. The current rsi is 43.46. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Entrada Therapeutics Inc Daily Relative Strength Index (RSI) ChartEntrada Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Entrada Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Entrada Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Entrada Therapeutics Inc Daily Stochastic Oscillator ChartEntrada Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Entrada Therapeutics Inc. The current cci is -98.50379662.

Entrada Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEntrada Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Entrada Therapeutics Inc. The current cmo is -16.01342828.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Entrada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEntrada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Entrada Therapeutics Inc. The current willr is -76.37540453.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Entrada Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Entrada Therapeutics Inc Daily Williams %R ChartEntrada Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Entrada Therapeutics Inc.

Entrada Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Entrada Therapeutics Inc. The current atr is 0.7859761.

Entrada Therapeutics Inc Daily Average True Range (ATR) ChartEntrada Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Entrada Therapeutics Inc. The current obv is 2,836,903.

Entrada Therapeutics Inc Daily On-Balance Volume (OBV) ChartEntrada Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Entrada Therapeutics Inc. The current mfi is 34.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Entrada Therapeutics Inc Daily Money Flow Index (MFI) ChartEntrada Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Entrada Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Entrada Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Entrada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.463
Ma 20Greater thanMa 5013.070
Ma 50Greater thanMa 10013.140
Ma 100Greater thanMa 20014.002
OpenGreater thanClose12.230
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Entrada Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Entrada Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Entrada Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Entrada Therapeutics Inc

I send you an email if I find something interesting about Entrada Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Entrada Therapeutics Inc.

Receive notifications about Entrada Therapeutics Inc in your mailbox!